Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 2/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365972 | 0.82 | L3MBTL1 (0.52) | PIK3C3 | |
| SCHEMBL29951814 | 0.82 | L3MBTL1 (0.52) | PIK3C3 | |
| SCHEMBL2555419 | 0.80 | EGFR (0.42) | GCK | |
| SCHEMBL12062550 | 0.79 | NPC1 (0.54) | — | |
| SCHEMBL22809551 | 0.78 | TYK2 (0.50) | KDM4EMAP4K1 | |
| SCHEMBL5777715 | 0.78 | LMNA (0.47) | KDM4EABL1 | |
| SCHEMBL18266478 | 0.78 | JAK2 (0.50) | KDM4E | |
| SCHEMBL22408359 | 0.78 | FGFR4 (0.57) | FGFR4PIK3C3APEX1TSHR | |
| SCHEMBL22809622 | 0.76 | RAB9A (0.45) | TSHR | |
| SCHEMBL22809499 | 0.75 | ACVRL1 (0.58) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008119569-A1 | SYNTHESIS OF ANTHRANILAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242866-A1 | SYNTHESIS OF ANTHRANILAMIDES | BAYER SCHERING PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242866-A1 | SYNTHESIS OF ANTHRANILAMIDES | BAYER SCHERING PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242866-A1 | SYNTHESIS OF ANTHRANILAMIDES | ANTXR2, QTRT1, NQO2 | FGFR4 4482/4885PIK3C3 3085/4885KDM4E 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.